# Incretin Biochemistry

> GIP and GLP-1 chemistry, the incretin effect, DPP-4 logic and modern GLP-1 therapeutics for MBBS Biochemistry.

- Canonical URL: https://prepelephant.com/topics/mbbs/biochemistry/incretin-biochemistry
- Exam / course: MBBS · Subject: Biochemistry
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Incretin Biochemistry", PrepElephant, https://prepelephant.com/topics/mbbs/biochemistry/incretin-biochemistry

## Direct answer

Oral glucose coaxes more insulin out of the pancreas than the same glucose given intravenously — the incretin effect, which contributes perhaps half to two-thirds of postprandial insulin through two peptide hormones: GIP from duodenal K cells and GLP-1 from ileal and colonic L cells. GLP-1 (cut from proglucagon by PC1/3 in the gut) raises cyclic AMP in beta cells glucose-dependently, suppresses glucagon, slows gastric emptying and acts on hindbrain and hypothalamic satiety circuits — but survives only a minute or two before DPP-4 removes its two N-terminal amino acids. That short half-life has generated two drug classes: the -gliptins that protect endogenous incretins by inhibiting DPP-4, and engineered GLP-1 receptor agonists, now joined by dual GIP/GLP-1 agents.

## What you must remember

- **Two hormones, two cells:** GIP (42 amino acids, K cells of duodenum and jejunum — "glucose-dependent insulinotropic polypeptide", renamed from gastric inhibitory polypeptide) and GLP-1 (the 7-36 amide, L cells of distal ileum and colon); nutrient arrival, not glucose alone, triggers both.
- **One gene, two hormones:** pancreatic glucagon and gut GLP-1 come from the same proglucagon gene — PC2 in the alpha cell yields glucagon, PC1/3 in the L cell yields GLP-1; a favourite viva point.
- **GLP-1 action set:** glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying (blunting postprandial excursions), central appetite reduction; in preclinical models, beta-cell proliferation and survival.
- **Glucose-dependence:** incretin-driven insulin release fades as glucose falls, so neither the hormones nor their drugs cause hypoglycaemia alone — the property separating them from sulfonylureas and insulin.
- **DPP-4 and the gliptins:** a ubiquitous peptidase that truncates GLP-1 within minutes; sitagliptin, vildagliptin, saxagliptin and linagliptin (heavily prescribed in India) raise intact incretin modestly, are weight-neutral and — because concentrations stay below the thresholds for gastric and central effects — do not reproduce the agonist profile.
- **Agonist chemistry:** exenatide is synthetic exendin-4 from Gila monster saliva (DPP-4-resistant); liraglutide and semaglutide use fatty-acyl albumin binding for daily or weekly dosing; oral semaglutide rides with the absorption enhancer SNAC; tirzepatide is a dual GIP/GLP-1 agonist.
- **Cautions:** nausea and vomiting (titrate), gallbladder disease, care with pancreatitis history and severe gastroparesis; rapid glycaemic improvement can transiently worsen proliferative retinopathy; a labelled contraindication applies in MEN2 and medullary thyroid carcinoma from rodent C-cell data.
- **Outcome evidence:** liraglutide and semaglutide showed cardiovascular benefit in their landmark trials — class evidence worth quoting, not a guarantee for every patient.

## Worked example: choosing between two prescriptions

Two patients with type 2 diabetes sit in the same clinic. The first, obese, with high post-meal spikes and established coronary disease, gets a GLP-1 receptor agonist: weight loss, blunted gastric emptying and cardiovascular outcome data all point the same way. The second, elderly, frail with borderline renal function and modest hyperglycaemia, is better served by linagliptin — weight-neutral, renally safe at standard dose, easy to take. The teaching question is why the gliptin does not simply reproduce the agonist: DPP-4 inhibition raises intact GLP-1 perhaps two- to three-fold, an order of magnitude below pharmacological agonism, so appetite and gastric effects never engage. Then counsel the first patient honestly about the first weeks of nausea and the injection technique — adherence, not pharmacokinetics, is where GLP-1 therapy most often fails.

## Where students slip

"Incretin" used loosely as a drug class rather than the two hormones. Assuming gliptins and agonists are interchangeable, missing the ten-fold concentration difference that separates their effect profiles. The classic fact worth stating: in type 2 diabetes the GLP-1 response is largely preserved while the GIP effect is impaired — the reason therapy builds on the GLP-1 arm.

## Frequently asked questions

### What is the incretin effect?

The observation that oral glucose evokes more insulin than intravenous glucose at matched glycaemia, attributed mainly to GIP and GLP-1.

### How can glucagon and GLP-1 arise from the same gene?

Tissue-specific prohormone convertases: PC2 in pancreatic alpha cells yields glucagon, while PC1/3 in intestinal L cells yields GLP-1.

### Why do DPP-4 inhibitors cause minimal hypoglycaemia and no weight loss?

They raise incretin concentrations only modestly within a glucose-dependent pathway, below the thresholds for appetite and gastric effects.

### Which incretin drug derives from Gila monster saliva?

Exenatide, a synthetic version of exendin-4 that is naturally resistant to DPP-4 degradation.

### Why is GLP-1 agonism avoided in MEN2 and medullary thyroid carcinoma?

Rodent studies showed C-cell thyroid tumours, so a labelled contraindication applies to humans at genetic risk, although a definite human signal remains debated.